News | May 04, 2021
Glenmark launches Ryaltris-AZ at affordable price
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Port chairpersons have been asked to personally supervise logistic operations to ensure unhindered movement of such consignments for berthing of such vessel on top priority in the port
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Subscribe To Our Newsletter & Stay Updated
